Biotech Company Beam Therapeutics Gains $135 Million in Series B
March 16, 2019
1:23 pm
![Biotech Company Beam Therapeutics Gains $135 Million in Series B](https://i0.wp.com/newscenter.io/wp-content/uploads/2019/03/Screen-Shot-2019-03-20-at-1.18.31-PM.png?fit=913%2C619&ssl=1)
Credit: beamtx.com
Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, completed a $135 million Series B financing. Participants included new investors Redmile Group, LLC, Cormorant Asset Management, GV, and Altitude Life Science Ventures, along with existing investors F-Prime Capital, ARCH Venture Partners, Eight Roads Ventures, and Omega Funds.
The company plans to use the funds to advance the company’s development of next-generation CRISPR technologies, expand its pipeline of base editing programs, and further extend its scientific and technical leadership.